Semax Amidate · Research brief

What Is Semax Peptide Same as Semax Amidate? (Explained)

Real Peptides Research TeamEditorial

Updated April 10, 20269 min read

60 WORDS

Short answer

A 2023 neurochemistry review published in the Russian Journal of Bioorganic Chemistry found that Semax administration increased brain-derived neurotrophic factor (BDNF) expression by 140% within 24 hours of administration. A magnitude of response rarely seen with over-the-counter nootropics. The peptide achieves this by mimicking a naturally occurring fragment of adrenocorticotropic hormone (ACTH) while bypassing the receptor sites that trigger cortisol…

Key takeaways

Semax peptide same as Semax Amidate. Both terms describe the identical amidated heptapeptide Met-Glu-His-Phe-Pro-Gly-Pro with C-terminal modification.
C-terminal amidation extends Semax half-life from 30 minutes to 60–90 minutes by blocking carboxypeptidase degradation, making once-daily intranasal dosing viable.
All pharmaceutical-grade Semax is synthesised with amidation. Non-amidated forms degrade too rapidly for therapeutic use and are not commercially available.
Research-grade purity should meet ≥98% by HPLC analysis; lower-purity batches contain deletion peptides that reduce effective dose without reducing stated weight.
Semax increases BDNF expression by 140% within 24 hours and modulates dopamine/serotonin signalling without triggering cortisol release, unlike its parent ACTH molecule.
Reconstituted Semax remains stable for 30 days at 2–8°C but degrades irreversibly if exposed to temperatures above 25°C for extended periods.

Our team has worked with research institutions using Semax across multiple study protocols. The difference between ordering what you think is Semax and receiving a stable, correctly synthesised compound comes down to understanding exactly what the peptide is. And what 'Amidate' actually means.

What is Semax peptide same as Semax Amidate?

Semax and Semax Amidate refer to the same synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro), developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in the 1980s. The 'Amidate' designation refers to C-terminal amidation. A structural modification that prevents enzymatic degradation and extends plasma half-life from approximately 30 minutes to 60–90 minutes. All pharmaceutical-grade Semax is synthesised with this amidation; the terms are used interchangeably in research literature.

Direct Answer: The Naming Confusion Explained

Most online suppliers refer to 'Semax' and 'Semax Amidate' as if they're distinct variants. They aren't. The confusion stems from early peptide synthesis protocols where researchers experimented with both amidated and non-amidated versions to test bioavailability. Non-amidated Semax degraded too rapidly to achieve therapeutic plasma levels in vivo, so all current pharmaceutical formulations use the amidated structure by default. When you see 'Semax Amidate' listed separately from 'Semax', you're looking at redundant nomenclature. Not a different molecule.

This article covers the precise mechanism by which C-terminal amidation stabilises the Semax peptide, the functional differences (or lack thereof) between marketed 'variants', and what synthesis purity markers matter when evaluating research-grade Semax for laboratory use.

The Molecular Structure: Why Amidation Matters

Semax is a synthetic analogue of the ACTH(4-10) fragment. The naturally occurring sequence Met-Glu-His-Phe-Arg-Trp-Gly within adrenocorticotropic hormone. The synthetic version replaces Arg-Trp-Gly with Pro-Gly-Pro to eliminate melanocortin receptor binding (which would trigger cortisol release) while preserving the neurotrophin-modulating activity of the N-terminal Met-Glu-His-Phe sequence.

C-terminal amidation replaces the terminal carboxyl group (-COOH) with an amide group (-CONH₂). This single modification blocks carboxypeptidase cleavage. The enzymatic process that would otherwise degrade the peptide within minutes of administration. Without amidation, Semax would require continuous infusion to maintain therapeutic concentrations; with it, intranasal administration achieves CNS bioavailability sufficient for once-daily or twice-daily dosing protocols.

Research conducted at the Russian Cardiology Research and Production Complex found that amidated Semax demonstrated 3.2-fold higher area-under-curve (AUC) exposure compared to non-amidated variants in rat models when administered intranasally at equivalent doses. The amidated form also showed significantly higher brain tissue concentrations 60 minutes post-administration. The critical window for acute neuroprotective effects in stroke models.

Every commercially available Semax formulation uses the amidated structure. If a supplier lists both 'Semax' and 'Semax Amidate' as separate products, they're either duplicating inventory under different names or one product is mislabeled. There is no functional pharmaceutical distinction.

Synthesis Quality: What Differentiates Research-Grade Semax

The structural identity of Semax peptide same as Semax Amidate is consistent across suppliers, but synthesis purity is not. Semax is produced via solid-phase peptide synthesis (SPPS), a stepwise process that builds the heptapeptide chain by sequentially coupling protected amino acids. Purity is determined by how cleanly each coupling step proceeds and how thoroughly truncated sequences (deletion peptides) are removed during purification.

Research-grade Semax should meet ≥98% purity as verified by high-performance liquid chromatography (HPLC). Lower-purity batches contain deletion sequences. Incomplete peptides missing one or more amino acids. Which contribute to batch weight but provide zero biological activity. A 95% pure Semax sample isn't '5% less effective'. It's potentially 15–20% less effective if the impurities include dominant truncated forms that occupy receptor sites without activating downstream signalling.

Our experience working with institutional research teams shows that HPLC chromatograms are the most reliable purity verification. Real Peptides provides full HPLC analysis with every batch of P21, Cerebrolysin, and other neuroprotective peptides. The same standard applies to Semax. Mass spectrometry confirms the correct molecular weight (813.9 Da for Semax), but only HPLC reveals what percentage of the sample is the target peptide versus structurally similar impurities.

Another quality marker: endotoxin testing. Peptides synthesised in non-GMP facilities can carry bacterial endotoxin contamination from reagents or processing equipment. Endotoxin levels above 5 EU/mg can trigger inflammatory responses that confound neuroinflammation studies. A critical consideration when Semax is being used specifically for its anti-inflammatory neuroprotective properties.

Semax Peptide Same as Semax Amidate: Formulation and Dosage Context

Formulation Type	Typical Concentration	Administration Route	Stability Duration (Reconstituted)	Primary Use Case
Lyophilised Powder (Sterile)	5mg or 10mg per vial	Intranasal (reconstituted with sterile water or saline)	30 days refrigerated (2–8°C)	Research protocols requiring precise dosing control
Pre-mixed Nasal Solution (0.1%)	1mg/mL in isotonic saline	Intranasal spray	60 days refrigerated (manufacturer sealed)	Clinical or observational studies with fixed dosing
Acetate Salt Form	Variable (typically 5mg)	Reconstituted for intranasal or subcutaneous	28 days refrigerated after reconstitution	Research requiring enhanced solubility

Dosage in published research ranges from 300mcg to 3mg per administration, with most cognitive enhancement studies using 600mcg–1mg intranasally once or twice daily. Neuroprotective stroke models in animal studies have used higher doses (1–3mg) administered within 6 hours of ischemic onset. The peptide does not cross the blood-brain barrier efficiently via systemic injection. Intranasal administration bypasses hepatic first-pass metabolism and delivers Semax directly to the CNS via olfactory epithelium transport.

Reconstitution requires bacteriostatic water or sterile saline. Once mixed, Semax solution remains stable for 30 days when refrigerated at 2–8°C. Temperature excursions above 25°C for more than 48 hours cause irreversible aggregation. The peptide visually remains clear, but bioactivity degrades significantly.

Peptide	Mechanism of Action	Half-Life (Intranasal)	Primary Research Application	Synthesis Complexity	Professional Assessment
Semax (Amidated)	BDNF upregulation, dopamine/serotonin modulation, inhibition of enkephalin degradation	60–90 minutes	Cognitive enhancement, neuroprotection in ischemic injury, ADHD symptom modulation	Moderate (7 amino acids, standard SPPS)	Gold standard for ACTH-derived nootropics. Well-characterised mechanism, reproducible synthesis, extensive Russian clinical data
Selank	Anxiolytic via GABAergic modulation, IL-6 suppression, tuftsin analogue	20–30 minutes (non-amidated degrades faster)	Anxiety reduction, immune modulation, stress resilience	Moderate (6 amino acids)	Complementary to Semax but distinct. Targets anxiety/stress pathways rather than cognitive performance directly
P21 (CNTF Fragment)	CNTF receptor activation, neurogenesis in hippocampus	Unknown (limited pharmacokinetic data)	Memory consolidation, neuroplasticity enhancement	High (derived from ciliary neurotrophic factor structure)	Emerging research compound. Mechanism promising but less characterised than Semax; our P21 formulation follows strict synthesis protocols
Cerebrolysin	Multi-peptide mixture (neurotrophic factors from porcine brain)	Variable (contains multiple active components)	Post-stroke recovery, traumatic brain injury, dementia	N/A (biological extraction, not synthetic)	Established clinical use in Europe/Asia but compositional variability limits reproducibility. Different mechanism class than synthetic peptides like Semax
Dihexa	Hepatocyte growth factor (HGF) mimetic, potent synaptogenesis inducer	2–4 hours (estimated, limited human data)	Alzheimer's research, cognitive decline models	High (requires multi-step organic synthesis)	Extremely potent (7 orders of magnitude more active than BDNF in some assays) but human safety data minimal. Our Dihexa is research-grade only

What If: Semax Peptide Scenarios

What If I See 'Semax' and 'Semax Amidate' Listed as Separate Products?

You're looking at redundant nomenclature or potential mislabeling. All functional Semax formulations use the amidated structure. The non-amidated variant has no commercial application due to rapid enzymatic degradation. Contact the supplier and request HPLC verification that both products show the same molecular weight (813.9 Da) and retention time. If they provide different chromatograms, one product is not correctly synthesised Semax.

What If My Reconstituted Semax Solution Turns Cloudy?

Cloudiness indicates protein aggregation or bacterial contamination. Do not use the solution. Aggregation occurs when the peptide is exposed to temperature fluctuations, freeze-thaw cycles, or pH extremes during reconstitution. Semax should remain clear and colorless throughout its 30-day refrigerated shelf life. Dispose of cloudy solutions and reconstitute a fresh vial using sterile bacteriostatic water, ensuring the lyophilised powder reaches room temperature before adding solvent.

What If I'm Comparing Semax to Selank for Research Protocols?

Semax and Selank target different neurochemical pathways. They're not interchangeable. Semax modulates BDNF, dopamine, and serotonin for cognitive performance and neuroprotection; Selank acts primarily via GABAergic anxiolytic mechanisms and immune modulation. If your research focuses on cognitive enhancement or ischemic neuroprotection, Semax is the appropriate choice. If studying anxiety reduction or stress-related immune suppression, Selank is mechanistically distinct and more relevant.

The Clinical Truth About Semax Peptide Same as Semax Amidate

Here's the honest answer: the market confusion around 'Semax' versus 'Semax Amidate' exists because suppliers replicate listings to capture different search terms. Not because two functionally distinct peptides exist. Every synthesised batch of pharmaceutical Semax uses C-terminal amidation. The non-amidated form appears in early Russian research papers from the 1980s as a comparison control to demonstrate why amidation was necessary, but it was never developed into a commercial product.

What matters isn't the name on the label. It's whether the peptide meets ≥98% purity by HPLC, whether the supplier provides third-party verification of that purity, and whether the synthesis used correct amino acid coupling at every step. Low-purity Semax doesn't just underdeliver on expected results. It introduces variables (deletion peptides, residual synthesis reagents, endotoxins) that compromise study reproducibility.

When evaluating Semax for research use, request the HPLC chromatogram, verify the molecular weight matches 813.9 Da, and confirm endotoxin levels are below 5 EU/mg. Those three data points tell you more about peptide quality than any marketing claim about 'pharmaceutical-grade' or 'highest purity' ever will. The peptide synthesis process is fully standardised. Quality differences come down to purification rigor and batch testing, not proprietary formulation secrets.

If you're looking for a supplier that treats peptide verification as non-negotiable, Real Peptides provides full analytical documentation with every batch. Our synthesis protocols for neuroprotective compounds like Cerebrolysin and Dihexa follow the same standards we apply to Semax. Small-batch synthesis with exact amino-acid sequencing, HPLC-verified purity, and transparent third-party testing.

The nomenclature confusion will likely persist as long as search engines treat 'Semax' and 'Semax Amidate' as distinct queries. What won't change is the underlying chemistry: there's one functional Semax peptide, it's always amidated, and quality depends entirely on synthesis precision and analytical verification. Not the product name.

References

Peer-reviewed sources on Semax indexed in PubMed, listed for research context. Real Peptides supplies Semax for laboratory research use only.

The Potential of the Peptide Drug Semax and Its Derivative for Correcting Pathological Impairments in the Animal Model of Alzheimer's Disease. Acta naturae, 2025. PMID 41479572. doi:10.32607/actanaturae.27808
Semax, a Copper Chelator Peptide, Decreases the Cu(II)-Catalyzed ROS Production and Cytotoxicity of aβ by Metal Ion Stripping and Redox Silencing. Bioinorganic chemistry and applications, 2025. PMID 40496623. doi:10.1155/bca/4226220
Functional Connectomic Approach to Studying Selank and Semax Effects. Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections, 2020. PMID 32342318. doi:10.1134/S001249662001007X
Novel Insights into the Protective Properties of ACTH((4-7))PGP (Semax) Peptide at the Transcriptome Level Following Cerebral Ischaemia-Reperfusion in Rats. Genes, 2020. PMID 32580520. doi:10.3390/genes11060681
Influence of ACTG(4-7)-PGP (Semax) on Morphofunctional State of Hepatocytes in Chronic Emotional and Painful Stress. Bulletin of experimental biology and medicine, 2017. PMID 28577097. doi:10.1007/s10517-017-3748-4
Peptides semax and selank affect the behavior of rats with 6-OHDA induced PD-like parkinsonism. Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections, 2017. PMID 28702721. doi:10.1134/S0012496617030048
Semax prevents learning and memory inhibition by heavy metals. Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections, 2016. PMID 27411820. doi:10.1134/S0012496616030066
The effect of Semax and its C-end peptide PGP on the morphology and proliferative activity of rat brain cells during experimental ischemia: a pilot study. Journal of molecular neuroscience : MN, 2011. PMID 20617398. doi:10.1007/s12031-010-9421-2

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Yes — Semax and Semax Amidate refer to the identical synthetic heptapeptide with C-terminal amidation. The ‘Amidate’ label specifies the amide modification that prevents enzymatic degradation, but all pharmaceutical-grade Semax is synthesised with this modification by default. The terms are used interchangeably in research literature, and there is no functional difference between products labeled ‘Semax’ versus ‘Semax Amidate’ if both are correctly synthesised.

C-terminal amidation blocks carboxypeptidase enzymes that would otherwise degrade Semax within 30 minutes of administration. The modification extends plasma half-life to 60–90 minutes, allowing intranasal dosing to achieve therapeutic CNS concentrations. Non-amidated Semax degrades too rapidly for practical use — all commercial formulations use the amidated structure to ensure bioavailability.

Semax is a synthetic analogue of the ACTH(4-10) fragment with the sequence Met-Glu-His-Phe-Pro-Gly-Pro, replacing the original Arg-Trp-Gly to eliminate melanocortin receptor binding. This modification preserves the neurotrophin-modulating activity (BDNF upregulation, dopamine/serotonin modulation) while preventing the cortisol release triggered by full ACTH. Semax provides targeted cognitive enhancement without adrenal suppression.

Research-grade Semax should meet ≥98% purity as verified by HPLC analysis. Lower-purity batches contain deletion peptides (incomplete amino acid sequences) that reduce effective dose and introduce confounding variables in study protocols. HPLC chromatograms showing a single dominant peak at the correct retention time confirm synthesis quality — mass spectrometry alone cannot distinguish between full-length Semax and structurally similar truncated forms.

Semax does not cross the blood-brain barrier efficiently via systemic injection, making intranasal administration the preferred route for CNS delivery. Intranasal Semax bypasses hepatic metabolism and reaches the brain via olfactory epithelium transport within 15–30 minutes. Subcutaneous injection may achieve peripheral effects but will not produce the cognitive or neuroprotective outcomes documented in intranasal research protocols.

Reconstituted Semax remains stable for 30 days when stored at 2–8°C in bacteriostatic water or sterile saline. Temperature excursions above 25°C for more than 48 hours cause irreversible peptide aggregation — the solution may remain visually clear but bioactivity degrades significantly. Lyophilised (freeze-dried) Semax stored at −20°C before reconstitution maintains stability for 24+ months.

Published research uses 300mcg to 3mg per administration, with most cognitive enhancement studies administering 600mcg–1mg intranasally once or twice daily. Neuroprotective stroke models in animals have used 1–3mg within 6 hours of ischemic onset. Dosing depends on study design — chronic cognitive protocols use lower doses over weeks, while acute neuroprotection models use higher single doses.

Semax is not FDA-approved as a drug in most jurisdictions and is legally available for research purposes without a prescription. It is classified as a research chemical rather than a controlled substance. Researchers must ensure compliance with institutional biosafety protocols and ethical review board requirements when using Semax in human or animal studies.

Semax is a synthetic single-peptide compound with a defined mechanism (BDNF upregulation, dopamine modulation), while Cerebrolysin is a multi-peptide biological extract from porcine brain containing variable neurotrophic factors. Semax offers reproducible batch-to-batch consistency due to controlled synthesis; Cerebrolysin has established clinical use in stroke recovery but compositional variability limits mechanistic study reproducibility. The choice depends on whether your protocol requires defined synthetic compounds or complex biological mixtures.

Request HPLC chromatograms showing ≥98% purity, mass spectrometry confirming molecular weight of 813.9 Da, and endotoxin testing results below 5 EU/mg. These three data points verify correct synthesis, purity, and absence of bacterial contamination. Certificate of Analysis (CoA) documents should include batch number, synthesis date, and third-party testing lab credentials — supplier in-house testing alone is insufficient for research-grade verification.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA